BioVie (BIVI) Stock Price, News & Analysis

Company Overview

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for complex diseases with significant unmet medical needs. Its research programs have centered on neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease, as well as liver diseases associated with cirrhosis.

The company’s development portfolio has included NE3107, an investigational oral therapy being studied for potential anti-inflammatory and insulin-sensitizing effects in neurodegenerative conditions. BioVie has also developed BIV201, a continuous-infusion formulation of terlipressin intended for the treatment of ascites associated with liver cirrhosis. These products remain investigational and are not approved for commercial use in the United States.

BioVie conducts its drug-development activities primarily through clinical research and regulatory programs in the United States, working with research institutions, clinical investigators and other development partners. The company is headquartered in Nevada and has historically focused its resources on advancing its candidate therapies through clinical testing and potential regulatory approval.

BioVie’s leadership has included Chief Executive Officer Cuong Do, who has experience in the biopharmaceutical and healthcare industries. As a development-stage biotechnology company, BioVie does not currently operate a broad commercial product business and remains dependent on the progress of its clinical programs.

Key Stats

• Today's Range: $1.12 to $1.22
• 50-Day Range: $0.96 to $2.28
• 52-Week Range: $0.82 to $3.79
• Volume: 275,347 shs
• Average Volume: 231,802 shs
• Market Capitalization: $10.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

BioVie Stock Analysis - MarketRank™

BioVie scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

BioVie has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

BioVie has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioVie is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioVie is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioVie has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.49% of the float of BioVie has been sold short.

Short Interest Ratio / Days to Cover

BioVie has a short interest ratio ("days to cover") of 2.73, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioVie has recently decreased by 20.53%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioVie does not currently pay a dividend.

Dividend Growth

BioVie does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for BioVie this week, compared to 2 articles on an average week.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of BioVie in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $49,118.00 in company stock, which represents 0.4714% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, BioVie insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,118.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

16.70% of the stock of BioVie is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

4.59% of the stock of BioVie is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/18/2026
• Next Earnings (Estimated): 11/09/2026
• AGM 2026: 11/10/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BIVI
• CIK: 1580149
• Web: bioviepharma.com
• Phone: (775) 888-3162
• Fax: N/A
• Employees: 13
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($3.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.07 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -126.02%
• Return on Assets: -108.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.59
• Quick Ratio: 3.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.36 per share
• Price / Book: 0.88

Miscellaneous

• Outstanding Shares: 8,683,000
• Free Float: 7,233,000
• Market Cap: $10.42 million
• Optionable: No Data
• Beta: 0.73